Title,Time,Link,Image URL,Teaser,Source Name
KOLs Discuss Atezolizumab & Bevacizumab in Liver Cancer,2024-09-10 09:30:00,https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice,https://medsii.azureedge.net/images/638615574121062047-66e010fe6157181811bbccee.jpg,"The article highlights the IMbrave150 trial, focusing on the combination of atezolizumab and bevacizumab for treating hepatocellular carcinoma (HCC). Key opinion leaders discuss their experiences and insights regarding the trial's efficacy data and its implications for clinical practice. The content emphasizes the importance of translating evidence into practice and includes links to related resources and events.",Google Alerts <googlealerts-noreply@google.com>
Rubella Infection Raises MS Risk in the Non-immunised,2024-09-10 09:20:00,https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/,https://medsii.azureedge.net/images/638615568331040849-66e00dfc6157181811bbccdd.jpg,"A Swedish study suggests that having antibodies against the rubella virus may increase the risk of developing multiple sclerosis (MS) in unvaccinated individuals. The research indicates that rubella infection could be a potential risk factor for MS, supporting the idea that certain viral infections may trigger the immune responses linked to the disease. The study found that unvaccinated MS patients had a significantly higher presence of rubella antibodies compared to healthy controls. Researchers caution that further studies are necessary to confirm these findings and understand the mechanisms involved, particularly the role of molecular mimicry.",Multiple Sclerosis News Today
Regeneron to use Digital Biomarkers in Parkinson's Trial,2024-09-10 09:05:00,https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study,https://medsii.azureedge.net/images/638615559431472528-66e00b5d6157181811bbccdb.jpg,"Regeneron has joined the LEARNS trial, a remote study by Koneksa, which uses digital biomarkers to monitor Parkinson's disease progression through smartphone and wearable tech. The trial, enrolling up to 70 participants over 12 months, aims to enhance the development of disease-modifying therapies. Regeneron, alongside MSD/Merck & Co, will have real-time access to trial data for analysis and design. The initiative seeks to improve quantitative measures in monitoring Parkinson's, addressing the challenges of relying on subjective assessments. Other projects, like the DREAM Challenge, also explore digital biomarkers for the disease.",Pharmaphorum
Diamyd Pursues FDA Accelerated Approval to Delay Type 1 Diabetes Worsening,2024-09-10 08:59:00,https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html,https://medsii.azureedge.net/images/638615555869451478-66e0088f4e2a8b3bb835601c.jpg,"Diamyd Medical is seeking accelerated approval from the U.S. FDA for its immunotherapy, Diamyd® (rhGAD65/alum), targeting Stage 3 Type 1 Diabetes. The company plans to base its Biologics License Application (BLA) on an upcoming interim readout from the DIAGNODE-3 Phase 3 trial, expected in March 2026. The trial, involving around 330 patients across Europe and the U.S., focuses on preserving insulin production. Diamyd® has received Fast Track designation, and the FDA may approve its use based on C-peptide levels as a surrogate endpoint.",PR Newswire ClinicalTrials Medical Discoveries
As­tra's Biological Fails Pri­ma­ry End­point in Phase 2 COPD Tri­al,2024-09-10 08:48:00,https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/,https://medsii.azureedge.net/images/638615549979129032-66e007544e2a8b3bb835600e.jpg,"AstraZeneca's anti-IL-33 monoclonal antibody did not succeed in a Phase 2a study for chronic obstructive pulmonary disease (COPD). However, the company reported some ""encouraging clinical efficacy signals"" despite the failure.",endpointnews
UK Funds Hospital Use of Merck's Welireg for Rare Genetic Disorder,2024-09-10 08:44:00,https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder,https://medsii.azureedge.net/images/638615546546870199-66e0060e6157181811bbccd0.png,"Welireg (belzutifan), an oral treatment for the rare genetic disorder von Hippel-Lindau (VHL) disease, will soon be available to patients in England and Wales through the NHS, following its approval in Scotland. The drug is recommended for adults with VHL-associated renal cell carcinoma, brain tumours, or pancreatic neuroendocrine tumours when surgery is not viable. This conditional recommendation by NICE follows a previous withholding due to evidence uncertainties. With approximately 100 eligible patients in England, the decision is viewed as a significant breakthrough, providing an alternative to invasive surgeries and radiotherapy.",Pharmaphorum
Longeviti Neuro Gets US Patent for Neurosurgical Brain Implant,2024-09-09 06:12:00,https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant,https://medsii.azureedge.net/images/638614591637377731-66de91004e2a8b3bb8355ea7.jpg,"Longeviti Neuro Solutions, a neurotechnology company in Maryland, has obtained a U.S. patent for its innovative prosthetic translucent cranial implant designed for neurosurgical procedures. The ClearFit implant integrates brain-computer interface capability, brain mapping, and neurosonography, enabling direct brain communication with external devices and real-time monitoring of brain activity during surgery. This advancement aims to enhance precision in neurological procedures and reduce costs and time associated with brain monitoring globally, according to Longeviti Neuro Solutions CEO Jesse Christopher.",Healio
mRNA Jab Gives More Mpox Protection vs. Licensed Version,2024-09-09 06:06:00,https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/,https://medsii.azureedge.net/images/638614587884468851-66de8f79ac48c5e342a26582.jpg,"A study funded by Moderna, NIAID, and NIH found that an investigational mRNA mpox vaccine outperformed the licensed Modified Vaccinia Ankara (MVA) vaccine in non-human primates. The mRNA vaccine significantly reduced symptoms, disease duration, and viral shedding compared to MVA, while all vaccinated animals survived lethal mpox exposure. The mRNA vaccine also demonstrated potential for cross-immunity against various Orthopoxviruses. The findings suggest mRNA technology could provide effective, safer vaccines for preventing mpox and related diseases. Moderna's mRNA-1769 vaccine is currently undergoing Phase I/II clinical trials.",Drug Target Review
FDA Grants Full Approval For Rare Kidney Disease Drug,2024-09-09 06:01:00,https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/,https://medsii.azureedge.net/images/638614584883118964-66de8eb66157181811bbcc29.jpg,"Traver Therapeutics has received full approval for Filspari (sparsentan), a treatment for a rare autoimmune disease impacting the kidneys. The drug had previously received accelerated approval.",endpointnews
GSK's Nucala Shows Positive Results in New COPD Trial,2024-09-09 05:56:00,https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial,https://medsii.azureedge.net/images/638614581666221290-66de8d32ac48c5e342a26581.jpg,"GSK's asthma treatment Nucala (mepolizumab) shows promise as a COPD therapy following positive results from the phase 3 MATINEE trial, which demonstrated a significant reduction in exacerbation rates compared to placebo. Although GSK faced setbacks in previous trials, the new findings could lead to regulatory discussions for extending Nucala's indications. The drug, already approved for severe eosinophilic asthma, generated £856 million in sales in the first half of 2023. With COPD affecting over 300 million people globally, Nucala could tap into a substantial market as new therapies emerge in the field.",Pharmaphorum
"Mg Valproate, Lamotrigine Ease Neuropsychiatric Symptoms in Encephalitis",2024-09-11 07:50:00,https://doi.org/10.1186/s12883-024-03811-z,https://medsii.azureedge.net/images/638616378267198844-66e14a35001b19ebcdecefde.jpg,"Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare autoimmune condition characterized by  due to an autoimmune reaction against the NMDAR. The study examines the efficacy of adjuvant therapies—olanzapine, magnesium valproate, and lamotrigine—alongside standard immunotherapy. Results indicate that magnesium valproate and lamotrigine significantly enhance cognitive and neurological functions while restoring the excitatory/inhibitory balance in the brain, compared to olanzapine. The study suggests that these adjuvant treatments may improve clinical outcomes in patients with anti-NMDAR encephalitis, although limitations such as sample size and retrospective design are acknowledged.",Springer Link
Diabetes Drug Metformin May Deplete HIV Reservoirs,2024-09-11 07:39:00,https://medicalxpress.com/news/2024-09-diabetes-drug-immune-reservoirs-hiv.html,https://medsii.azureedge.net/images/638616371770178330-66e1479da042693efa9b1736.jpg,"A study by Canadian researchers suggests that metformin, commonly used for type 2 diabetes, may help deplete and potentially eliminate the HIV viral reservoir in individuals receiving antiretroviral therapy. The research, led by Petronela Ancuta, demonstrated metformin's dual effects: enhancing immunity while inhibiting HIV replication in CD4 T lymphocytes. It boosts the BST2 protein, aiding immune recognition of infected cells. Ancuta envisions using metformin in a ""shock-and-kill"" strategy, alongside antibodies, to target and eliminate these cells. Future clinical trials are planned to validate these findings.",MedicalXpress
Mirtazapine Fails to Ease COPD Symptoms in Larger Trial,2024-09-11 07:23:00,https://www.hcplive.com/view/mirtazapine-fails-to-ease-breathlessness-in-new-study-despite-previous-hopes,https://medsii.azureedge.net/images/638616361814404885-66e14437a042693efa9b1735.jpg,"A phase 3 study has found that mirtazapine, an antidepressant, does not alleviate breathlessness in patients with respiratory diseases like COPD and interstitial lung diseases. Despite prior suggestions that it could modulate respiratory sensation, the trial showed no significant differences in breathlessness scores between mirtazapine and placebo groups. The study involved 225 participants and reported adverse events more frequently in the mirtazapine group. Researchers concluded that mirtazapine is not recommended for treating breathlessness and emphasized the necessity for rigorous testing of off-label medications in palliative care.",HCPLive
FDA Rare Disease Award for Radiopharmaceutical in Carcinomas,2024-09-11 07:16:00,https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-abd-147-in-neuroendocrine-carcinoma,https://medsii.azureedge.net/images/638616357706757383-66e1431fd832db8b2bed8e0a.jpg,"The FDA has granted orphan drug designation and fast track designation to ABD-147, a next-generation precision radiopharmaceutical therapy developed by Abdera Therapeutics, for treating neuroendocrine carcinoma, including small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). ABD-147 targets DLL3-expressing tumors, delivering actinium-225 to enhance treatment efficacy. A first-in-human study is set to begin in 2024 for patients previously treated with platinum-based therapies. The designations provide incentives for development, including tax credits and potential market exclusivity.",Targeted Oncology
Lilly's Weekly Insulin Matches Daily Injections in Type II Diabetes,2024-09-11 07:10:00,https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html,https://medsii.azureedge.net/images/638616354194383390-66e14139a042693efa9b1727.jpg,"Eli Lilly announced results from the QWINT-2 phase 3 trial, evaluating insulin efsitora alfa, a once-weekly basal insulin, in adults with type 2 diabetes. The trial demonstrated that efsitora reduced A1C levels by 1.34%, achieving A1C of 6.87%, compared to 1.26% and 6.95% for insulin degludec. Efsitora also provided 45 more minutes in glucose range daily without increasing hypoglycemia risk. The findings were published in The New England Journal of Medicine and presented at the EASD Annual Meeting 2024, highlighting efsitora's potential to improve treatment adherence and reduce diabetes management complexity.",PR Newswire ClinicalTrials Medical Discoveries
Spanish Launch for Piflufolastat Diagnostic in Prostate Cancer,2024-09-12 07:20:00,https://www.urologytimes.com/view/piflufolastat-18f-enters-commercial-market-in-spain,https://medsii.azureedge.net/images/638617224445950507-66e292f1d832db8b2bed8f40.jpg,"Piflufolastat (18F), marketed as Pylclari, is now available in Spain for detecting PSMA-positive lesions in prostate cancer patients using PET imaging. Developed by Curium, it was approved in the U.S. in May 2021. The tracer aids in staging high-risk prostate cancer and localizing recurrences. Following its EU marketing authorization in July 2023, it is now available in seven countries, including Spain. Clinical trials demonstrated its high specificity, sensitivity, and positive predictive value, with minimal adverse events reported. The availability of Pylclari marks a significant advancement in prostate cancer diagnostics.",Urology Times
Gut Mucosal Damage Raises Risk of Parkinson's,2024-09-12 07:01:00,https://www.hcplive.com/view/upper-gi-mucosal-damage-linked-increased-risk-parkinson-disease,https://medsii.azureedge.net/images/638617212944368991-66e29039d832db8b2bed8f3f.jpg,"A recent study published in JAMA Network Open suggests that a history of upper gastrointestinal mucosal damage may increase the risk of developing Parkinson disease (PD). Analyzing data from nearly 20,000 patients who underwent upper endoscopy, researchers found that those with mucosal damage had a significantly higher likelihood of being diagnosed with PD compared to those without damage. The study highlights the need for further investigation into the relationship between gastrointestinal health and PD, emphasizing the importance of monitoring patients with mucosal damage for potential PD risk.",HCPLive
Clinical Scale Validated for Detecting Early Catheter Infection in Hemodialysis,2024-09-12 06:49:00,https://www.healio.com/news/nephrology/20240910/researchers-validate-clinical-scale-for-early-catheter-infection-detection-in-hemodialysis,https://medsii.azureedge.net/images/638617205484084346-66e28d95001b19ebcdecf0d4.jpg,"A study validated a clinical scale for early detection of infections at the exit site of central venous catheters (CVC) in hemodialysis patients with chronic kidney disease. Conducted across nine hospitals in Spain, the multicenter study involved 337 CVCs and identified key symptoms for the scale: pain during dialysis, hyperemia of at least 2 cm, and purulent exudate. The scale demonstrated high efficacy with an area under the curve of 88.3%, sensitivity of 80.34%, and specificity of 95.23%. Its use enhances early detection, treatment, and uniformity in monitoring exit-site infections, potentially improving patient outcomes and care continuity.",Healio
FDA Awards Orphan Status for Cilnidipine in Systemic Sclerosis,2024-09-12 06:37:00,https://www.prnewswire.com/news-releases/aisa-pharma-receives-fda-orphan-drug-designation-for-aisa-021-for-treatment-of-systemic-sclerosis-302242199.html,https://medsii.azureedge.net/images/638617198437006866-66e28b29a042693efa9b17cd.jpg,"Aisa Pharma, Inc. announced that its drug AISA-021 (cilnidipine) received orphan drug designation from the FDA for treating Systemic Sclerosis (SSc), a severe autoimmune disease affecting 175,000 Americans. This designation may expedite development and offers various incentives. Preliminary Phase 2 study results show AISA-021 improved symptoms and had fewer side effects compared to existing therapies. Aisa plans to present two abstracts at the upcoming ACR Convergence Scientific Meeting in November 2024 and is seeking partners to support further development. AISA-021 is distinguished by its selectivity for N-type calcium channels and potential pain relief capabilities.",PR Newswire FDA Approval
Diabetes Raises Gum Disease Risk Study Shows,2024-09-12 06:30:00,https://www.eurekalert.org/news-releases/1057199,https://medsii.azureedge.net/images/638617194073977251-66e289d3d832db8b2bed8f3d.jpg,"Recent research presented at the EASD annual meeting highlights a link between gum disease and microvascular complications in individuals with diabetes. A study of over 15,000 participants with type 2 diabetes found that those with diabetic retinopathy and neuropathy had significantly higher risks of moderate to severe periodontitis. The presence of dyslipidaemia further increased these risks. Researchers emphasize the importance of a multidisciplinary approach in treatment, urging dentists to screen diabetic patients for microvascular complications, which could enhance both oral and overall health outcomes.",Eureka News
Positive Trial Results for Dupixent in Uncontrolled COPD ,2024-09-12 06:25:00,https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-10-10-30-00-2943464,https://medsii.azureedge.net/images/638617191007040140-66e2880ed832db8b2bed8f3c.png,"A pooled analysis from the BOREAS and NOTUS phase 3 studies presented at the 2024 European Respiratory Society Congress demonstrated that Dupixent significantly reduces exacerbations (31% decrease) and improves lung function in adults with uncontrolled COPD and type 2 inflammation. Approved in the EU as the first biologic for this condition, Dupixent shows promise in enhancing treatment for COPD patients already on standard inhaled therapy. Safety profiles were consistent with prior studies, and regulatory reviews are ongoing in multiple countries. Sanofi and Regeneron continue to explore Dupixent's efficacy in treating type 2 inflammation-related diseases.",Google Alerts <googlealerts-noreply@google.com>
Latest Guidance to Prevent Surgical Site Infections in Colorectal Surgeries,2024-09-16 07:11:00,https://www.clinicaladvisor.com/features/surgical-site-infection-prevention/,https://medsii.azureedge.net/images/638620674947809151-66e7d963eb7808a67efb0a32.jpg,"The American Society of Colon and Rectal Surgeons (ASCRS) has published a clinical practice guideline aimed at preventing surgical site infections (SSIs) during colorectal surgeries. This guideline, based on a review of 139 studies, includes 18 recommendations covering institutional, preoperative, intraoperative, and wound care interventions. Key findings emphasize the importance of care bundles, oral antibiotics combined with mechanical bowel preparation, proper hair removal techniques, timely antibiotic administration, and the use of wound protectors. The guideline aims to provide evidence-based strategies for healthcare professionals and patients to minimize SSI risks in colorectal operations.",Google Alert - Antibiotics
New ALS Blood Test Reaches 98% Accuracy in Diagnosis,2024-09-16 07:04:00,https://www.news-medical.net/news/20240913/New-blood-test-achieves-9825-accuracy-in-diagnosing-ALS.aspx,https://medsii.azureedge.net/images/638620670617328136-66e7d7e0eb7808a67efb0a31.jpg,"A new, highly accurate diagnostic blood test for amyotrophic lateral sclerosis (ALS) has been developed. This test aims to improve the diagnosis of ALS, a progressive neurodegenerative disease that affects neurons in the brain and spinal cord.",News Medical Life Sciences
Radium-223 + Xtandi Improves Outcomes in Prostate Cancer,2024-09-16 07:00:00,https://www.targetedonc.com/view/radium-223-enhances-outcomes-with-enzalutamide-in-metastatic-castration-resistant-prostate-cancer,https://medsii.azureedge.net/images/638620668173755948-66e7d6b1200d2676c39ea05b.jpg,"The phase 3 PEACE-3 trial demonstrated that combining radium-223 (Xofigo) with enzalutamide (Xtandi) significantly improves radiological progression-free survival (rPFS) and overall survival (OS) in patients with advanced prostate cancer and bone metastases. The trial involved patients from 12 countries, showing a median rPFS of 19.4 months for the combination compared to 16.4 months for monotherapy. OS was also improved with the combination (42.3 months vs. 35.0 months). However, the combination led to more adverse effects, highlighting the need for further data before widespread use.",Targeted Oncology
FDA Orphan Status to Plozasiran for Familial Chylomicronemia Syndrome,2024-09-16 06:54:00,https://www.hcplive.com/view/fda-grants-breakthrough-therapy-designation-to-plozasiran-for-fcs,https://medsii.azureedge.net/images/638620664674432091-66e7d553eb7808a67efb0a2f.jpg,"The FDA has granted Breakthrough Therapy designation to plozasiran, an investigational treatment for lowering triglycerides in adults with familial chylomicronemia syndrome (FCS). Arrowhead Pharmaceuticals plans to submit a New Drug Application by the end of 2024. Plozasiran, a first-in-class RNA interference therapeutic, showed significant triglyceride reduction in a Phase 3 study, with a median decrease of 80% at 10 months. The designation aims to expedite the development of therapies for serious conditions. Plozasiran has also received Orphan Drug and Fast Track designations and is being studied for other hyperlipidemia conditions.",HCPLive
Itepekimab Reduces Exacerbation Events in Ex-smokers with COPD,2024-09-16 06:50:00,https://www.healio.com/news/pulmonology/20240913/itepekimab-lowers-exacerbation-rate-in-former-smokers-with-copd,https://medsii.azureedge.net/images/638620661978646655-66e7d400200d2676c39ea058.jpg,"Itepekimab led to a 51% lower adjusted annualized exacerbation rate in former smokers with moderate/severe COPD and exacerbation history, according to a poster presented at the European Respiratory Society International Congress.

Exacerbations contribute to progressive lung function and worsen quality of life, so the potential to reduce these events is essential for any investigational COPD treatment.
Itepekimab is currently in two phase 3 trials, which have completed enrollment, and results are expected in the second half of next year.
",Healio
Diabetes Risk Raised with Increased Ultra-Processed Food Intake,2024-09-16 06:42:00,http://dx.doi.org/10.1016/j.lanepe.2024.101043,https://medsii.azureedge.net/images/638620657636236042-66e7d260200d2676c39ea04d.jpg,"A study by UCL researchers, published in The Lancet Regional Health – Europe, links increased consumption of ultra-processed foods (UPF) to a higher risk of type 2 diabetes. Analyzing data from over 311,000 individuals across Europe, the study found a 17% increase in diabetes risk for every 10% rise in UPF intake. Key high-risk UPF include savory snacks and processed meats. However, substituting UPF with less processed foods can reduce this risk, with significant reductions noted when replacing UPF with minimally processed options. The study emphasizes the need for further research to understand these associations.",Eureka News
MHRA Approves Dupilumab for Uncontrolled COPD,2024-09-17 13:02:00,https://pharmaceutical-journal.com/article/news/mhra-approves-dupilumab-for-treatment-of-uncontrolled-copd,https://medsii.azureedge.net/images/638621749651906926-66e97d24eb7808a67efb0b4e.jpg,"The MHRA has approved dupilumab (Dupixent) as an add-on maintenance treatment for adults with uncontrolled COPD, targeting type 2 inflammation in 30-40% of patients. This approval follows positive results from two phase III trials, notably the NOTUS trial, which demonstrated a 34% reduction in COPD exacerbations and improved lung function. Common side effects were similar to those observed in other indications of dupilumab. Experts view this approval as a significant advancement for COPD treatment, pending NICE recommendations for NHS use. COPD affects about 3 million people in the UK, leading to numerous hospital admissions annually.",Google Alert - Dupixent
Lenacapavir More Effective Than Daily PrEP Truvada in Preventing HIV Infection,2024-09-17 12:58:00,https://www.contagionlive.com/view/lenacapavir-reduces-hiv-infections-by-96-demonstrates-superiority-over-another-hiv-prophylactic,https://medsii.azureedge.net/images/638621747129918090-66e97b00eb7808a67efb0b4d.jpg,"Gilead announced that its injectable HIV capsid inhibitor, lenacapavir (Sunlenca), is more effective than the daily PrEP pill, Truvada, in preventing HIV infection. Results from the PURPOSE 2 phase 3 trial showed a 99.9% prevention rate with lenacapavir, compared to a 96% relative risk reduction versus Truvada. The trial included diverse participants across multiple countries, and both medications were well-tolerated. Gilead plans to expedite access to lenacapavir, particularly in low-resource countries, and aims for regulatory approvals to make it widely available. The findings suggest lenacapavir could significantly impact HIV prevention efforts.",Contagion Live
MYL-1701P Biosimilar Equivalent Compared With Aflibercept in Diabetic Macular Edema,2024-09-17 12:46:00,https://www.ajmc.com/view/myl-1701p-efficient-safe-compared-with-aflibercept-in-diabetic-macular-edema,https://medsii.azureedge.net/images/638621739589018798-66e9790d427e3fe2df75fb71.jpg,"A study published in JAMA Ophthalmology indicates that MYL-1701P, a biosimilar to aflibercept, is effective and safe for treating diabetic macular edema. Conducted across 77 sites in 9 countries, the phase 3 trial involved 355 participants and demonstrated comparable efficacy, safety, and immunogenicity to aflibercept after one year of treatment. Both drugs showed similar improvements in best corrected visual acuity and central subfield thickness. MYL-1701P offers a viable alternative to aflibercept, although the study noted a lack of racial diversity among participants.",Google Alert - Aflibercept
Mitsubishi Pharma to Present Latest Neurodegenerative Research at 2024 American Neurological Association Meeting,2024-09-17 13:27:00,https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-latest-neurodegenerative-research-at-the-2024-american-neurological-association-149th-annual-meeting-302245698.html,https://medsii.azureedge.net/images/638621764495835324-66e982dfeb7808a67efb0b4f.jpg,"Mitsubishi Tanabe Pharma America, Inc. (MTPA) is set to present findings on ND0612 for Parkinson's disease and RADICAVA ORS® (edaravone) for ALS at the American Neurological Association (ANA) 2024 Annual Meeting in Orlando, Florida. The presentations include two studies on ND0612's efficacy and infusion site reactions, and two on the comparative efficacy of RADICAVA ORS's daily dosing versus the approved regimen in ALS patients.",PR Newswire ClinicalTrials Medical Discoveries
FDA Orphan Drug Designation for SMT-M01 in Duchenne Muscular Dystrophy,2024-09-17 13:20:00,https://www.prnewswire.com/news-releases/somite-therapeutics-announces-fda-orphan-drug-and-rare-pediatric-disease-designations-for-smt-m01-in-duchenne-muscular-dystrophy-302248051.html,https://medsii.azureedge.net/images/638621760419194263-66e97e2b427e3fe2df75fb72.jpg,"Somite Therapeutics announced that the FDA has granted Orphan Drug and Rare Pediatric Disease Designations for its lead program, SMT-M01, aimed at treating Duchenne muscular dystrophy (DMD). The program utilizes Somite's AI-driven AlphaStem platform for cell replacement therapy. Additionally, the designations offer benefits like tax credits and market exclusivity upon approval. ",PR Newswire FDA Approval
Abemaciclib & ET Outperforms Paclitaxel in Advanced Breast Cancer,2024-09-17 13:34:00,https://www.targetedonc.com/view/abemaciclib-with-et-outperforms-chemotherapy-in-advanced-breast-cancer,https://medsii.azureedge.net/images/638621768490824158-66e98436427e3fe2df75fb74.jpg,"The ABIGAIL study presented at the 2024 ESMO Congress evaluated the efficacy of abemaciclib combined with endocrine therapy (ET) versus paclitaxel in patients with hormone receptor-positive/HER2-negative advanced breast cancer. The phase 2 trial included 162 patients and found a higher overall response rate (ORR) of 58.8% for abemaciclib and ET compared to 40.2% for paclitaxel. Safety profiles were comparable, though abemaciclib showed a higher incidence of diarrhea. The study aims to challenge the standard use of chemotherapy in this patient population and is ongoing to assess long-term efficacy and progression-free survival.",Targeted Oncology
FDA Orphan Drug Designation for SMT-M01 in DMD,2024-09-17 13:20:00,https://www.prnewswire.com/news-releases/somite-therapeutics-announces-fda-orphan-drug-and-rare-pediatric-disease-designations-for-smt-m01-in-duchenne-muscular-dystrophy-302248051.html,https://medsii.azureedge.net/images/638621760419194263-66e97e2b427e3fe2df75fb72.jpg,"Somite Therapeutics announced that the FDA has granted Orphan Drug and Rare Pediatric Disease Designations for its lead program, SMT-M01, aimed at treating Duchenne muscular dystrophy (DMD). The program utilizes Somite's AI-driven AlphaStem platform for cell replacement therapy. Additionally, the designations offer benefits like tax credits and market exclusivity upon approval. ",PR Newswire FDA Approval
MYL-1701P Biosimilar Hits Equivalence With Aflibercept in Diabetic Macular Edema,2024-09-17 12:46:00,https://www.ajmc.com/view/myl-1701p-efficient-safe-compared-with-aflibercept-in-diabetic-macular-edema,https://medsii.azureedge.net/images/638621739589018798-66e9790d427e3fe2df75fb71.jpg,"A study published in JAMA Ophthalmology indicates that MYL-1701P, a biosimilar to aflibercept, is effective and safe for treating diabetic macular edema. Conducted across 77 sites in 9 countries, the phase 3 trial involved 355 participants and demonstrated comparable efficacy, safety, and immunogenicity to aflibercept after one year of treatment. Both drugs showed similar improvements in best corrected visual acuity and central subfield thickness. MYL-1701P offers a viable alternative to aflibercept, although the study noted a lack of racial diversity among participants.",Google Alert - Aflibercept
Pfizer's Ponsegromab Treats Cachexia in Trial Participants,2024-09-18 06:10:00,https://pharmaphorum.com/news/esmo-pfizer-drug-helps-cancer-patients-gain-weight,https://medsii.azureedge.net/images/638622366528871602-66ea6dfd427e3fe2df75fbb5.jpg,"Pfizer's anti-GDF-15 antibody, ponsegromab, has shown promising results in treating cancer-related cachexia, a severe metabolic syndrome with no approved treatments. Data presented at the ESMO congress revealed that ponsegromab increased weight by 5.6% in patients, surpassing the clinically meaningful threshold. The phase 2 trial involved 187 patients with cachexia linked to various cancers, showing weight gains of up to 4.6% and improvements in appetite, physical activity, and muscle mass. Pfizer plans to initiate a phase 3 study next year and is also testing the drug in heart failure patients. Cachexia affects approximately 9 million people globally.",Pharmaphorum
"Cannabidiol Alleviates Symptoms in Leigh Syndrome, Rare CNS Disease",2024-09-18 06:04:00,https://medicalxpress.com/news/2024-09-cannabidiol-alleviate-symptoms-leigh-syndrome.html,https://medsii.azureedge.net/images/638622362871641426-66ea6c5e200d2676c39ea1f3.jpg,"A study by UAB Institut de Neurociències published in Nature Communications reveals that daily cannabidiol (CBD) administration can extend lifespan and alleviate symptoms of Leigh syndrome, a severe mitochondrial disease in children. The research shows CBD improves cellular function and offers antioxidant, anti-inflammatory, and anticonvulsant effects. In animal models, it enhanced brain health, breathing, and social behavior, while also prolonging life. The findings highlight CBD's potential as a treatment, supported by its orphan drug designation from the European Medicines Agency, and aim to facilitate its clinical application for Leigh syndrome patients.",MedicalXpress
Ventilator-associated Pneumonia: Lung Microbiome Profiles Better Predict Outcomes,2024-09-18 05:58:00,https://www.hcplive.com/view/lung-microbiome-profiling-promising-approach-enhance-diagnostic-precision-for-ventilator-associated-pneumonia,https://medsii.azureedge.net/images/638622358838388018-66ea6b09eb7808a67efb0b88.jpg,"﻿Ventilator-associated pneumonia (VAP) poses a significant challenge in ICUs, affecting many patients on invasive mechanical ventilation, particularly during the COVID-19 pandemic. The LUCID-IMHO study, funded by the American Lung Association, aims to create a microbiome-based diagnostic framework for VAP. Utilizing advanced DNA metagenomics and real-time sequencing, the study assesses microbial dynamics in critically ill patients. Significant findings indicate that lung microbiome profiles predict clinical outcomes better than traditional methods, emphasizing the need for targeted antibiotic use. The study's insights could transform VAP management, reduce unnecessary antibiotics, and improve patient outcomes in critical care settings.",HCPLive
New Quarterly Respiratory Report Newsletter Available,2024-09-18 05:51:00,https://www.hcplive.com/view/welcome-to-the-respiratory-report,https://medsii.azureedge.net/images/638622354944821004-66ea69cc200d2676c39ea1f2.jpg,"HCPLive introduces ""The Respiratory Report,"" a quarterly newsletter featuring updates on pulmonary research supported by the American Lung Association.The inaugural issue highlights studies by experts on various respiratory conditions, including osteogenesis imperfecta's impact on lung function, educational interventions for hypersensitivity pneumonitis, microbiome diagnostics for ventilator-associated pneumonia, and a tool to assess respiratory infection risks in schools. The newsletter aims to provide diverse insights into advancements in pulmonology, emphasizing the importance of expert-led research in improving respiratory health and patient outcomes.",HCPLive
FDA Approves Implantable CGM with Built-in Sensor Lasting 1 Year,2024-09-18 05:47:00,https://www.healio.com/news/endocrinology/20240917/fda-clears-implantable-cgm-with-sensor-that-lasts-up-to-1-year,https://medsii.azureedge.net/images/638622352318181818-66ea687e427e3fe2df75fbb3.jpg,"The FDA has approved the Eversense 365, a continuous glucose monitoring (CGM) system featuring an implantable sensor that lasts up to one year for adults with type 1 or type 2 diabetes. This innovative system includes a removable smart transmitter that provides real-time data to a mobile app and sends vibration alerts to the user. It can also integrate with compatible medical devices like insulin pumps. Scheduled for a U.S. launch in Q4 2024, the Eversense 365 represents a significant advancement in CGM technology, offering enhanced longevity and connectivity for diabetes management.",Healio
FDA Approves Pembrolizumab/Chemotherapy First-Line Use in Advanced Mesothelioma,2024-09-19 07:52:00,https://www.targetedonc.com/view/fda-approves-frontline-pembrolizumab-chemotherapy-in-advanced-mesothelioma,https://medsii.azureedge.net/images/638623291367570175-66ebd796200d2676c39ea2d6.jpg,"The FDA has approved pembrolizumab (Keytruda) combined with chemotherapy as a first-line treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma. This decision is based on the KEYNOTE-483 trial results, which demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone. The combination reduced the risk of death by 21%, with median OS of 17.3 months versus 16.1 months for chemotherapy alone. The overall response rate was also notably higher at 62% with the combination treatment. Safety profiles were consistent with previous reports.",Targeted Oncology
Molnupiravir Modestly Lowers Risk of Severe COVID-19 Symptoms ,2024-09-19 07:47:00,https://www.healio.com/news/infectious-disease/20240918/molnupiravir-cuts-risk-for-severe-covid19-symptoms-and-possibly-long-covid,https://medsii.azureedge.net/images/638623288814372145-66ebd659427e3fe2df75fc65.jpg,"A recent randomized controlled trial indicates that the antiviral molnupiravir modestly reduces the risk of severe COVID-19 symptoms and may lower the risk of long COVID. The PANORAMIC trial showed that while molnupiravir did not reduce hospitalization risk for vaccinated adults, it accelerated recovery by four days. Among over 25,000 participants, treatment led to fewer and less severe symptoms, with modest effect sizes. Experts suggest that while antivirals can help high-risk individuals, their impact on long COVID is limited, and further research is needed to optimize their use in prevention and treatment.",Healio
FDA Lifts Clinical Hold on VG-3927 Treatment for Neurodegenerative Disease,2024-09-19 07:41:00,https://www.clinicaltrialsarena.com/news/fda-lifts-hold-vigil-trial/,https://medsii.azureedge.net/images/638623284669266260-66ebd4ea191936c4d1e7cacd.jpg,"The FDA has lifted the partial clinical hold on Vigil Neuroscience's Phase I trial for VG-3927, a treatment for neurodegenerative diseases. Following a complete response from Vigil, interim findings indicated VG-3927's safety, tolerability, and pharmacokinetic profile support further exploration, including once-daily dosing. The trial has expanded to include Alzheimer’s patients, assessing biomarker responses. Vigil plans to release full Phase I data, including results from the Alzheimer’s cohort, in Q1 next year. VG-3927 aims to address microglial dysfunction in Alzheimer's, with positive initial efficacy signals noted.",Clinical Trials Arena
FDA Orphan Drug Status to Vaxinia in Cholangiocarcinoma,2024-09-19 07:35:00,https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-cf33-hnis-in-cholangiocarcinoma,https://medsii.azureedge.net/images/638623281258558475-66ebd349427e3fe2df75fc56.jpg,"The FDA has granted orphan drug designation to CF33-hNIS (Vaxinia) for treating cholangiocarcinoma. This genetically engineered oncolytic virus is being investigated in the MAST trial, assessing its efficacy alone and with pembrolizumab in patients with advanced solid tumors. The trial aims to determine safety and optimal dosing, with preliminary results showing an overall response rate of 14% and high disease control rates. CF33-hNIS is well tolerated, with no severe treatment-related adverse effects reported. The designation provides development incentives for treatments addressing rare diseases affecting fewer than 200,000 individuals in the U.S.",Targeted Oncology
Dupilumab Lowers COPD Exacerbation Rates Regardless of BODE Score,2024-09-19 07:25:00,https://www.healio.com/news/pulmonology/20240918/bode-index-score-does-not-change-dupilumab-efficacy-in-copd-with-type-2-inflammation,https://medsii.azureedge.net/images/638623275226789891-66ebd10c191936c4d1e7cacc.jpg,"A study presented at the European Respiratory Society Congress showed that dupilumab significantly reduces exacerbation rates and improves lung function in adults with COPD and type 2 inflammation, regardless of their BODE index score, which predicts mortality risk. The phase 3 BOREAS study involved 939 adults and found that those taking dupilumab experienced a 28.2% and 34.4% reduction in exacerbations for lower and higher BODE scores, respectively. The treatment also improved pre-bronchodilator FEV1. Researchers emphasize the potential of dupilumab across varying patient severities and plan further studies in real-world settings.",Healio
Bacterial Infections May Trigger Type 1 Diabetes,2024-09-19 07:20:00,https://medicalxpress.com/news/2024-09-bacterial-infections-trigger-diabetes.html,https://medsii.azureedge.net/images/638623272303941583-66ebd038200d2676c39ea2b9.jpg,"Researchers have discovered that bacterial proteins can activate killer T-cells, leading to the destruction of insulin-producing cells and the onset of type 1 diabetes. This study, led by Professor Andrew Sewell at Cardiff University, highlights how these T-cells mistakenly target insulin cells after encountering specific bacterial proteins. The findings, published in the Journal of Clinical Investigation, suggest that understanding this mechanism could lead to improved diagnosis and treatment strategies for type 1 diabetes, which currently has no cure and requires lifelong insulin management.",MedicalXpress
New Data Bolsters First-Line Combo Approach in Kidney Cancer,2024-09-20 06:44:00,https://www.targetedonc.com/view/first-line-treatment-for-kidney-cancer-new-data-strengthens-combo-approach,https://medsii.azureedge.net/images/638624114412447624-66ed192a191936c4d1e7cb10.jpg,"A post hoc analysis from the CheckMate-9ER study reveals that increased fucosylation and sialylation of serum proteins are negative prognostic indicators for advanced renal cell carcinoma (RCC) patients treated with nivolumab plus cabozantinib or sunitinib. High levels of specific glycopeptides may predict better responses to the combination therapy over sunitinib. This exploratory research suggests the need for further investigation into glycopeptide biomarkers for RCC treatment outcomes, highlighting the potential role of protein glycosylation in cancer prognosis and therapy response. The study was presented at the 2024 ESMO Congress.",Targeted Oncology
Neurodegenerative Disorders Detected by Leptin Deficiency,2024-09-20 06:38:00,https://medicalxpress.com/news/2024-09-higher-leptin-brain-late-life.html,https://medsii.azureedge.net/images/638624110791211292-66ed176c191936c4d1e7cb0f.jpg,"New research from UT Health San Antonio links obesity to dementia, highlighting the role of leptin, a hormone regulating body weight. Higher leptin levels correlate with improved brain white matter integrity in middle-aged adults, suggesting its deficiency could signal early cognitive impairment related to Alzheimer's or vascular dementia. The study involved 2,262 participants from the Framingham Heart Study and found that leptin markers were associated with cognitive function and brain health. These findings underscore leptin's potential neuroprotective role, indicating that managing obesity may reduce dementia risk.",MedicalXpress
$100m Funding Allows UK Biotech to Refile Rejected Antifungal,2024-09-20 06:33:00,https://pharmaphorum.com/news/armed-100m-funding-f2g-prepares-refile-antifungal,https://medsii.azureedge.net/images/638624107769823360-66ed15e4200d2676c39ea330.jpg,"UK biotech F2G has raised $100 million to advance the development of its oral antifungal candidate, olorofim, for invasive fungal infections after a previous FDA rejection. The funding will support late-stage trials and regulatory review, aiming to address the lack of new therapies for such infections. Olorofim, a novel orotomide antifungal, targets serious conditions like invasive aspergillosis, particularly in immunocompromised patients. The financing was led by the AMR Action Fund, highlighting the urgent need for new treatments as existing options face rising resistance. F2G retains North American rights while Shionogi holds licenses in Europe and Asia.",Pharmaphorum
FDA Orphan Drug Status for ATSN-201 in X-linked Retinoschisis,2024-09-20 06:25:00,https://www.healio.com/news/ophthalmology/20240917/fda-grants-orphan-drug-designation-for-atsn201-for-xlinked-retinoschisis,https://medsii.azureedge.net/images/638624103152617863-66ed14c3200d2676c39ea32e.jpg,"Atsena Therapeutics announced that its gene therapy ATSN-201 has received orphan drug designation from the FDA for treating X-linked retinoschisis (XLRS), a condition with no approved treatments. The therapy aims to address the genetic cause of XLRS through a one-time subretinal injection. The designation offers benefits like market exclusivity and tax credits for clinical trials. The company is currently enrolling participants in a phase 1/2 trial and plans to include pediatric patients soon, while also preparing for discussions with the FDA regarding a phase 3 trial.",Healio
GLP-1 Drugs Decrease HbA1c & Body Weight in Type 1 Diabetes,2024-09-20 06:20:00,https://www.healio.com/news/endocrinology/20240919/offlabel-semaglutide-tirzepatide-lower-hba1c-and-body-weight-in-type-1-diabetes,https://medsii.azureedge.net/images/638624099940948841-66ed1345427e3fe2df75fd06.jpg,"Adults with type 1 diabetes using off-label semaglutide or tirzepatide experienced significant reductions in body weight and HbA1c compared to those not on these medications. A study found that tirzepatide users had a 21.4% weight loss and a 0.68% decrease in HbA1c, while semaglutide users lost 9.1% of their body weight and had a 0.54% HbA1c reduction. Both treatments were associated with decreased insulin requirements, and no serious adverse events were reported. Researchers emphasize the need for randomized controlled trials to further evaluate these medications' efficacy and safety in this population.",Healio
COPD Drugs Anticipated for Next Medicare Price Negotiation,2024-09-20 06:14:00,https://pharmaphorum.com/news/icer-mulls-gsk-copd-drugs-ahead-next-medicare-negotiation,https://medsii.azureedge.net/images/638624096568354710-66ed11ff191936c4d1e7cb0e.jpg,"The Institute for Clinical and Economic Review (ICER) anticipates that a COPD drug will be included in the next round of Medicare price negotiations, despite not being officially involved. ICER previously contributed to a report on Eliquis and Xarelto, which are part of the first negotiation list. It is now preparing a report on GSK's COPD therapies, Breo Ellipta and Trelegy Ellipta, expected to be reviewed for negotiations next year. The Centers for Medicare & Medicaid Services will announce the next 15 drugs by February 1, 2024, with negotiated prices effective January 1, 2027.",Pharmaphorum
